共 50 条
- [1] Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialLANCET ONCOLOGY, 2019, 20 (12): : 1691 - 1701Shaw, Alice T.Solomon, Benjamin J.Chiari, RitaRiely, Gregory J.Besse, BenjaminSoo, Ross A.Kao, StevenLin, Chia-ChiBauer, Todd M.Clancy, Jill S.Thurm, HolgerMartini, Jean-FrancoisPeltz, GersonAbbattista, AntonelloLi, SherryOu, Sai-Hong Ignatius
- [2] Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialLANCET ONCOLOGY, 2017, 18 (12): : 1590 - 1599Shaw, Alice T.Felip, EnriquetaBauer, Todd M.Besse, BenjaminNavarro, AlejandroPostel-Vinay, SophieGainor, Justin F.Johnson, MelissaDietrich, JorgJames, Leonard P.Clancy, Jill S.Chen, JosephMartini, Jean-FrancoisAbbattista, AntonelloSolomon, Benjamin J.
- [3] Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyLANCET RESPIRATORY MEDICINE, 2024, 12 (09): : 671 - 680Yang, Jin-JiZhou, JianyingLiu, Si-Yang MaggieLi, MingjunZhang, ZhiyeCheng, YingFan, YunPan, HongmingWang, BaoqingChen, GongyanWang, KeJiang, LiyanHu, YanpingShi, JianhuaDong, XiaorongDing, CuiminLiu, YunpengLiu, ZheLiao, WangjunLi, WeiWang, JunYi, ShanyongZhao, QiongZang, AiminChen, YuanCui, JiuweiLuo, PengfeiShen, XionghuSun, MeiliWang, ChangliWu, Yi-Long
- [4] Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialLANCET ONCOLOGY, 2016, 17 (05): : 642 - 650Planchard, DavidKim, Tae MinMazieres, JulienQuoix, ElisabethRiely, GregoryBarlesi, FabriceSouquet, Pierre-JeanSmit, Egbert F.Groen, Harry J. M.Kelly, Ronan J.Cho, B. C.Socinski, Mark A.Pandite, LiniNase, ChristineMa, BoD'Amelio, Anthony, Jr.Mookerjee, BijoyeshCurtis, C. Martin, Jr.Johnson, Bruce E.
- [5] Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancerCANCER RESEARCH, 2024, 84 (07)Li, ZimingDang, XiaominHuang, DingzhiJin, ShiLi, WeiweiShi, JianhuaWang, XichengZhang, YipingSong, ZhengboZhang, JunpingZhuang, WuLiu, XuewenJiang, LiyanMeng, XiangjiaoZhao, MingfangZhou, JianyingZhang, LiangmingWang, PingliLuo, HuiYang, JunquanCang, ShundongWang, XiangWang, JingCui, JiuweiYu, YanZhang, ZhihongLu, JunguoYang, WeihuaLi, GaofengFeng, JifengLv, DongqingWu, LinFang, YongWang, YanZhao, YanqiuCao, BaoshanZhu, WeiZhuang, ZhixiangLi, QingshanWang, MingxiZhou, HuanDong, XiaorongHu, ShengFang, JianZhang, YihongWang, WenjiaXiang, ZiyongShi, ZheZhang, LingLu, Shun
- [6] Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialLANCET ONCOLOGY, 2016, 17 (12): : 1653 - 1660Drilon, AlexanderRekhtman, NatashaArcila, MariaWang, LuNi, AndyAlbano, MelanieVan Voorthuysen, MartineSomwar, RomelSmith, Roger S.Montecalvo, JosephPlodkowski, AndrewGinsberg, Michelle S.Riely, Gregory J.Rudin, Charles M.Ladanyi, MarcKris, Mark G.
- [7] Safety of Lorlatinib in Patients with Unresectable Advanced ALK -Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in IndiaINDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2025,Batra, UllasGupta, Vineet G.Raut, NirmalPatil, TusharPanchal, HarshaGhadyalpatil, NikhilPathak, AnandDesai, ChiragBondarde, ShaileshJain, MinishReyes, Christian RusselParvatini, ShyamPai, SeemaToffalorio, FrancescaThurm, HolgerBiswas, Bivas
- [8] Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trialLANCET ONCOLOGY, 2020, 21 (06): : 786 - 795Shu, Catherine A.Gainor, Justin F.Awad, Mark M.Chiuzan, CodrutaGrigg, Claud M.Pabani, AliyahGarofano, Robert F.Stoopler, Mark B.Cheng, Simon K.White, AbbyLanuti, MichaelD'Ovidio, FrankBacchetta, MatthewSonett, Joshua R.Saqi, AnjaliRizvi, Naiyer A.
- [9] Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialLANCET ONCOLOGY, 2020, 21 (11): : 1413 - 1422Provencio, MarianoNadal, ErnestInsa, AmeliaRosario Garcia-Campelo, MariaCasal-Rubio, JoaquinDomine, ManuelMajem, MargaritaRodriguez-Abreu, DelvysMartinez-Marti, AlexDe Castro Carpeno, JavierCobo, ManuelLopez Vivanco, GuillermoDel Barco, EdelBernabe Caro, ReyesVinolas, NuriaBarneto Aranda, IsidoroViteri, SantiagoPereira, EvaRoyuela, AnaCasarrubios, MartaSalas Anton, ClaraParra, Edwin R.Wistuba, IgnacioCalvo, VirginiaLaza-Briviesca, RaquelRomero, AtochaMassuti, BartomeuCruz-Bermudez, Alberto